Meet iSTAR Medical’s new logo

Let us introduce you to iSTAR Medical’s new logo. Our ‘eye’ embeds our purpose: improving the vision and lives of patients with glaucoma through powerful and safe ophthalmic implants with bio-integration. The foundation of our technology is the proprietary, microporous, anti-fibrotic STAR® material, combined with intuitive access into the supraciliary space. The unique outcomes: powerful enhancement of […]

MINIject’s STAR-I and II trial data to be presented at ESCRS

Positive results from two clinical trials of iSTAR Medical’s micro-invasive glaucoma surgery (MIGS) implant MINIjectTM  will be presented at the European Society of Cataract and Refractive Surgery (ESCRS) meeting on October 2-4.

MINIject’s data presented at Ophthalmology Futures Forum

CEO Michel Vanbrabant will present positive outcomes for iSTAR Medical’s MIGS device MINIjectTM in over 130 glaucoma patients at the Ophthalmology Futures Forum today.

Positive outcomes for iSTAR Medical’s MIGS MINIject shown in trials of over 130 glaucoma patients

Pooled data confirm excellent safety and efficacy profile with very low rate of reintervention

Journal of Glaucoma published MINIject six-month clinical data

Successful primary endpoint results of MINIject in the European clinical trial STAR-II have been published in the peer-reviewed Journal of Glaucoma. The data confirm that MINIject met the study primary endpoints with over 75 percent of patients reaching prospectively defined success.